Navigation Links
Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2007 Financial Results
Date:3/26/2008

ults for the fourth quarters of 2007 and 2006 include non-cash charges relating to stock-based compensation of $79,260 and $150,796, respectively.

As a development stage pharmaceutical company, Catalyst had no revenues during 2007 and 2006.

At December 31, 2007, the Company had cash and cash equivalents totaling $15.9 million and no long-term debt. The Company believes that its existing cash and cash equivalents will be sufficient to meet its projected operating requirements through the middle of 2009.

Company Development Update

In August 2007, Catalyst submitted to the U.S. Food & Drug Administration (FDA) the results of a bioequivalence study demonstrating that CPP-109 is bioavailable and bioequivalent to Sabril(R) Tablets, the version of vigabatrin marketed in Europe by Sanofi Aventis.

In December 2007, Catalyst announced positive initial top-line results from a Catalyst-supported, investigator-initiated, Phase II double-blind, placebo-controlled trial, in which vigabatrin met its primary efficacy endpoint of abstinence during the last weeks of treatment for cocaine addiction. Additional results of this trial will be reported when they become available. This 103-subject trial is the first randomized, double-blind, placebo-controlled clinical trial studying vigabatrin's effectiveness in treating cocaine addiction. These data show that a statistically significantly greater number of subjects treated with vigabatrin were able to abstain from cocaine usage during the last three weeks of the dosing period compared to those receiving placebo. Achievement of abstinence for an extended period during treatment is the critical first step for cocaine addicted patients to potentially achieve abstinence for much longer time periods. The data confirm the positive results seen in two previous open-label trials conducted in 2003 and 2004.

In January 2008, Catalyst announced that it has initiated enrollment of patients for its 180-patient
'/>"/>

SOURCE Catalyst Pharmaceutical Partners
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 BreedIT Corp (OTC: BRDT), ... distributor of highly sophisticated agro-breeding solutions for plant breeders ... the Company,s board of directors appointed chemistry and pharmaceutical ... new member of the board. From 1975 ...
(Date:1/15/2014)... GARDENS, Fla. , Jan. 15, 2014  In an unprecedented effort ... and TB in ambulances and other transport vehicles, an advanced and ... by rescue personnel for the first time. In ... contact with these deadly pathogens, West Palm Beach ...
(Date:1/15/2014)... 15, 2014 MultiCell Technologies, Inc. (OTC Bulletin Board: ... patent application concerning composition of matter, biological targets, mechanism ... cell death.  This patent application describes ... RNA molecules (VSRNAs) which interfere with the basic homeostatic ...
Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Superbugs No Longer Ride In Rescue Vehicles 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
... Oct. 24, 2011 PhotoMedex , Inc. (NASDAQ: ... including the XTRAC® excimer laser ( www.XTRACLaser.com ), is offering ... XTRAC psoriasis treatments for children, an underserved population of ... presented in recognition of World Psoriasis Day ...
... 24, 2011 HealthWarehouse.com, Inc. (OTC: HEWA), a ... it will begin providing prescription medications for WhiteGlove ... "We,re excited to have a national partner ... areas," said Robert Fabbio, co-founder and chief executive ...
Cached Medicine Technology:PhotoMedex Increases Access to Care for Children in Recognition of World Psoriasis Day, Oct. 29 2PhotoMedex Increases Access to Care for Children in Recognition of World Psoriasis Day, Oct. 29 3PhotoMedex Increases Access to Care for Children in Recognition of World Psoriasis Day, Oct. 29 4WhiteGlove Health Selects HealthWarehouse.com to Provide Prescription Medications to its Members Nationwide 2
(Date:7/10/2014)... July 10, 2014 Ticketability.com has a wide ... now Paul McCartney tickets for San Diego are being added ... Diego since 1976, and the newly added September 28 show ... , Click Here to view the selection of ... Petco Park will become available to the general public on ...
(Date:7/10/2014)... D.C. (PRWEB) July 10, 2014 One ... for Bangladesh Worker Safety announced today it will extend ... to four months’ wages for workers displaced as a ... To date, Alliance inspections have resulted in the closure ... in all five cases, raising immediate safety concerns. In ...
(Date:7/10/2014)... 2014 According to a new ... Platforms (Land, Airborne, Naval), Application (Software Defined Radios, ... Geography (North America, Asia-Pacific, Europe, the Middle East ... by MarketsandMarkets, the market is estimated to be ... register a CAGR of 5.56% to reach $39.52 ...
(Date:7/10/2014)... In his latest blog post at http://www.perwickstrom.com , ... Wickstrom has listed 5 ways to follow-up without being ... get information or sometimes even just return an inquiry, ... a skill that most people don’t have,” commented Per ... dialogue moving without coming across as annoying – let ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 A ... program that gets clients off to a great start ... can believe in, has launched a new Eating Disorders ... The new section highlights:, , Different ... Statistic Manual of Mental Disorders (DSM-IV), including anorexia nervosa, ...
Breaking Medicine News(10 mins):Health News:Paul McCartney Tickets for San Diego: Ticketability.com Announces Discounted Tickets for McCartney’s Tour Stop at Petco Park on September 28 2Health News:Alliance for Bangladesh Worker Safety to Double Compensation for Displaced Factory Workers; Members Vote to Extend Wage Benefits from Two to up to Four Months 2Health News:Portable Communication Systems Market Projected to Reach $39.52 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Portable Communication Systems Market Projected to Reach $39.52 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Portable Communication Systems Market Projected to Reach $39.52 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Per Wickstrom’s Latest Blog Post Lists 5 Ways to Follow-up Without Being Annoying 2Health News:Latest A Forever Recovery Launches Eating Disorders Section on Website 2
... May 15 Gerson Lehrman Group, the world,s,leading ... a Web-based community devoted to providing patients with ... own healthcare.,iGuard.org provides personalized iGuard Risk Ratings, iGuard ... their experience with other registered,users who also want ...
... of healthcare and medical device experience to board ... of fast-growing ... the first and only flexible CO2 laser scalpel enabling new procedures ... to the company,s board of directors. Suennen, co-founder and,managing member of ...
... /Xinhua-PRNewswire/ -- Tiens Biotech Group (USA), Inc.,(the ,Company, or ,Tiens,), ... for the first quarter ended March 31, 2008., Revenue ... to,$16.2 million for the first quarter of 2007., Net ... or $0.05 per,share, compared to net income of $6.5 million, ...
... a Cranergy(TM) ... Fuel Station in NYC,s Penn Station, LAKEVILLE-MIDDLEBORO, Mass., May ... country and lift people from,America,s other energy crisis. With hectic, ... at multi-tasking, most,people need an extra boost to keep them ...
... of altruism; helping others ... one,s own health issues, CHICAGO, May 15 Meet Cindy Zamirowski, ... "cancer,free" thumbs up from her physician, stepped off the curb to raise ... The Bolingbrook mom of three and grandma of three rallied her ...
... DURHAM, N.C. -- By targeting and disabling a protein frequently ... the cancer more vulnerable to chemotherapy, according to a new ... We tested a compound that can weaken the tumor by ... cell. When chemotherapy was applied to the tumor in this ...
Cached Medicine News:Health News:Gerson Lehrman Group and iGuard, Inc. Partner to Offer Patients a Voice in Healthcare Industry Decisions 2Health News:Gerson Lehrman Group and iGuard, Inc. Partner to Offer Patients a Voice in Healthcare Industry Decisions 3Health News:Lisa M. Suennen Joins OmniGuide(R) Board of Directors 2Health News:Tiens Biotech Group (USA) Reports First Quarter Results 2Health News:Tiens Biotech Group (USA) Reports First Quarter Results 3Health News:Tiens Biotech Group (USA) Reports First Quarter Results 4Health News:Tiens Biotech Group (USA) Reports First Quarter Results 5Health News:Tiens Biotech Group (USA) Reports First Quarter Results 6Health News:Tiens Biotech Group (USA) Reports First Quarter Results 7Health News:Tiens Biotech Group (USA) Reports First Quarter Results 8Health News:Tiens Biotech Group (USA) Reports First Quarter Results 9Health News:Tiens Biotech Group (USA) Reports First Quarter Results 10Health News:Tiens Biotech Group (USA) Reports First Quarter Results 11Health News:Video: Ocean Spray Revitalizes Americans Naturally With Free Fuel for Their Bodies 2Health News:After Effects: Giving Back Is Good for You 2Health News:Targeted therapy plus chemotherapy may pack 1-2 punch against melanoma 2
... helps you deliver unmatched performance through patient-focused ... the most complete anesthesia solution developed, putting ... - at your fingertips., ,The Aisys ... legacy of anesthesia delivery and patient monitoring ...
... Premilene Mesh LP Self-Forming Plug is combining ... This results in a very soft hernia plug ... to standard Plugs less foreign body material is ... the hernia size and shape allows for a ...
... Celsius Control System provides physicians,with ... safely,and rapidly lower patient body ... temperature and,rewarm patients to normothermic ... consists of an endovascular,catheter, console ...
... Fiberoptics Gemini surgical headlight is perfectly balanced ... durable and ultra-low-profile and illuminates brilliantly while ... annoying "rams effect." The fully adjustable headband, ... to sit low on the brow, directing ...
Medicine Products: